Gilles Salles
YOU?
Author Swipe
View article: Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma Open
Most patients diagnosed with mantle cell lymphoma (MCL) experience extended remissions following frontline chemoimmunotherapy, yet with with extended follow-up, relapses seem nearly inevitable. This study aimed to define the genomic landsc…
View article: Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma Open
Introduction: Bispecific antibodies (BsAbs) are a powerful therapeutic modality in B-cell malignancies but are associated with distinct toxicities. Despite growing recognition of the clinical importance of immunosuppression and infections …
View article: Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study
Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study Open
Introduction: CAR-T is associated with a spectrum of acute toxicities, including acute cardiovascular events (CVE). The long-term cardiovascular outcomes after acute CVEs are not fully understood. Methods: We retrospectively studied adult …
View article: Spectrum, molecular features, and clinical outcomes of hematologic malignancies and clonal hematopoiesis in li fraumeni syndrome
Spectrum, molecular features, and clinical outcomes of hematologic malignancies and clonal hematopoiesis in li fraumeni syndrome Open
Background: Li Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by germline pathogenic variants in the TP53 gene. The classic LFS tumor spectrum includes sarcoma, breast, brain, and adrenocortical cancers. Hematologic mal…
View article: Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma
Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma Open
Background: Frontline mantle cell lymphoma (MCL) treatments are rapidly evolving with incorporation of targeted therapies. We previously demonstrated the safety and efficacy of the BOVen triplet (Zanubrutinib, Obinutuzumab, and Venetoclax)…
View article: Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial
Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial Open
Background: The incorporation of novel agents such as brentuximab vedotin (BV) and immune checkpoint blockade (ICB) into salvage therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) has significantly improved long-…
View article: Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial
Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial Open
Background Patients with relapsed/refractory (RR) DLBCL ineligible for chimeric antigen receptor T-cell therapy and/or autologous stem cell transplant (CART/ ASCT) or with progressive disease after CART/ASCT represent a major unmet need. 3…
View article: Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium
Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium Open
Background: BsAb have significantly improved outcomes for patients (pts) with multiply relapsed FL. However, with the availability of several therapeutic options for R/R FL, the appropriate sequencing of BsAb is unclear. Hence, we sought t…
View article: Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas
Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas Open
Background: CD20xCD3 bispecific antibodies (BsAb) are a transformative therapy for B-cell non-Hodgkin lymphomas (B-NHL), effective even post–CAR T cell therapy. While durable remissions occur, relapse is frequent and resistance mechanisms …
View article: Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma
Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma Open
Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T‐cell therapy, and yet, their dose‐specific impact on…
View article: Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure Open
View article: PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study Open
Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-related quality of life (HRQoL). The phase 3 POLARIX study (NCT03274…
View article: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma Open
In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492 ), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituxima…
View article: Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses
Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses Open
Obesity has been associated with non‐Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B‐cell lymphoma (DLBCL), follic…
View article: VALIDATION OF NONINVASIVE CLINICAL PATHWAYS TO IDENTIFY ADVANCED
VALIDATION OF NONINVASIVE CLINICAL PATHWAYS TO IDENTIFY ADVANCED Open
Introduction and Objectives: Limited data exist on non-invasive clinical algorithms for MetALD and ALD. We aimed to (1) quantify the false-negative rate of standard algorithms combining Fibrosis-4 index (FIB-4) and vibration-controlled tra…
View article: VALIDATION OF AGILE-3+ AND AGILE-4 SCORES FOR NONINVASIVE DETECTION OF FIBROSIS AND CIRRHOSIS IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE IN LATIN AMERICA
VALIDATION OF AGILE-3+ AND AGILE-4 SCORES FOR NONINVASIVE DETECTION OF FIBROSIS AND CIRRHOSIS IN METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE IN LATIN AMERICA Open
Introduction and Objectives: Early detection of liver fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is crucial for preventing progression to cirrhosis. The Agile-3+ and Agile-4 scores are designed to identify…
View article: Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era Open
View article: Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma Open
View article: Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma Open
Although 3 commercial CD19-targeted chimeric antigen receptor (CAR) T-cell therapies are available for large B-cell lymphomas (LBCLs), no randomized clinical trials have compared their efficacy and safety. In this retrospective multicenter…
View article: Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma
Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma Open
Not available.
View article: Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis Open
The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are unde…
View article: Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies Open
View article: Corrigendum to ‘Clinical Practice Recommendations for Hematopoietic Cell Transplantation.’ Transplant Cell Ther. 2024 Sep;30(9):832-843.
Corrigendum to ‘Clinical Practice Recommendations for Hematopoietic Cell Transplantation.’ Transplant Cell Ther. 2024 Sep;30(9):832-843. Open
View article: BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants
BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants Open
Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a type of T-cell lymphoma arising near textured breast implants. In a Dutch population, a higher prevalence of BRCA1/2 was found in BIA-ALCL. We analyzed the risk of BI…
View article: 184 | GENOMIC PROFILING OF EXTRANODAL DISEASE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A COMBINED ANALYSIS OF POLARIX AND GOYA
184 | GENOMIC PROFILING OF EXTRANODAL DISEASE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A COMBINED ANALYSIS OF POLARIX AND GOYA Open
View article: 288 | FIVE‐YEAR ANALYSIS OF AN ASIA SUBPOPULATION WITH PREVIOUSLY UNTREATED DLBCL CONFIRMS POLA‐R‐CHP BENEFIT ON OUTCOMES: THE POLARIX STUDY
288 | FIVE‐YEAR ANALYSIS OF AN ASIA SUBPOPULATION WITH PREVIOUSLY UNTREATED DLBCL CONFIRMS POLA‐R‐CHP BENEFIT ON OUTCOMES: THE POLARIX STUDY Open
View article: 24 | UNVEILING FOLLICULAR LYMPHOMA HETEROGENEITY: A SINGLE‐CELL ATLAS REVEALS PROGNOSTIC CELLULAR ECOSYSTEMS AND NOVEL BIOMARKERS ASSOCIATED WITH HIGH‐RISK
24 | UNVEILING FOLLICULAR LYMPHOMA HETEROGENEITY: A SINGLE‐CELL ATLAS REVEALS PROGNOSTIC CELLULAR ECOSYSTEMS AND NOVEL BIOMARKERS ASSOCIATED WITH HIGH‐RISK Open
View article: 734 | REAL‐WORLD OUTCOMES OF FRONTLINE BRENTUXIMAB VEDOTIN IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐AN INTERNATIONAL, MULTI‐CENTER STUDY
734 | REAL‐WORLD OUTCOMES OF FRONTLINE BRENTUXIMAB VEDOTIN IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐AN INTERNATIONAL, MULTI‐CENTER STUDY Open
View article: 161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM
161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM Open
View article: 858 | OPTIMIZING FRONTLINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA IN OLDER ADULTS: A GLOfitamab‐BASED, RESPONSE‐ADAPTED, WINDOW‐StYle STUDY (GLORY)
858 | OPTIMIZING FRONTLINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA IN OLDER ADULTS: A GLOfitamab‐BASED, RESPONSE‐ADAPTED, WINDOW‐StYle STUDY (GLORY) Open